Efficacy and Safety of Vedolizumab with Glucocorticoids vs Infliximabin Severe Ulcerative Colitis: A Retrospective Study.

At 30 weeks, the clinical response rate reached 91.30% in group A and 56.52% in group B, a highly significant difference between the two groups (χ2 = 7.216, p = 0.007), further indicating that group A performed better than group B in terms of clinical response over time.

also in 132,142 other papers